Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.

David S. Metzger,Deborah Donnell,David D. Celentano,J. Brooks Jackson,Yiming Shao,Apinun Aramrattana,Liu Wei,Liping Fu,Jun Ma,Gregory M. Lucas,Marek C. Chawarski,Yuhua Ruan,Paul G. Richardson,Katherine Shin,Ray Y. Chen,Jeremy Sugarman,Bonnie J. Dye,Scott Rose,Geetha Beauchamp,David N. Burns

Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.

2015

Background Injection opioid use plays a significant role in the transmission of HIV infection in many communities and several regions of the world. Access to evidence-based treatments for opioid use disorders is extremely limited.

Keywords:

Buprenorphine/naloxone
Immunology
Buprenorphine
Opiate Substitution Treatment
Intensive care medicine
Substance use treatment
Medicine
Opioid
Psychiatry
Prevention trials
Psychological intervention
Drug
Anesthesia
Dosing
Randomized controlled trial
Randomization
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations